This time next year, we will be preparing to stop the trial and analyse the results. We hope to be able to share the results with trial participants and trial staff a few months later in 2026. In the meantime, we are as busy as ever making sure that all the information that we have collected from participants during the trial is ready for immediate analysis in Leeds as soon as the last patients have stopped taking capsules.
A big ‘thank you’ to all participants who also provided samples that will enable us to investigate how EPA treatment is working. We are looking to see whether the gut bacteria that live naturally in the bowel make a difference to the effectiveness of EPA. Samples have been transferred to Boston in the USA and the experiments have started in the Harvard laboratory.
As ever, the Leeds team extend their heartfelt gratitude to all patients and research staff for their support and commitment to the EMT2 trial.